ACADIA Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Catherine Owen Adams
Chief executive officer
US$7.6m
Total compensation
| CEO salary percentage | 3.2% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.1yrs |
| Board average tenure | 9.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$8m | US$246k | US$226m |
Compensation vs Market: Catherine's total compensation ($USD7.59M) is above average for companies of similar size in the UK market ($USD3.03M).
Compensation vs Earnings: Insufficient data to compare Catherine's compensation with company performance.
CEO
Catherine Owen Adams (53 yo)
less than a year
Tenure
US$7,594,107
Compensation
Ms. Catherine E. Owen Adams is CEO & Director of ACADIA Pharmaceuticals Inc. from September 23, 2024. Ms. Owen Adams served as Director of OptiNose US, Inc. since July 2020 until September 24, 2024. She se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$7.59m | no data | |
| Executive VP & CFO | 3.6yrs | US$2.52m | 0.036% $ 871.7k | |
| Executive VP and Head of Research & Development | 1yr | US$4.35m | no data | |
| Executive VP | 1.3yrs | US$3.31m | 0.00061% $ 14.9k | |
| Consultant | less than a year | US$12.21m | 0.11% $ 2.7m | |
| Executive VP & Chief Commercial Officer | less than a year | US$4.18m | no data | |
| Chief People Officer | 3.3yrs | no data | no data | |
| Senior Vice President of Finance | no data | no data | 0.013% $ 326.2k | |
| Chief Business Officer | 1.8yrs | no data | no data |
1.1yrs
Average Tenure
51.5yo
Average Age
Experienced Management: 0A4W's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$7.59m | no data | |
| Independent Director | 16.9yrs | US$403.22k | 0.012% $ 295.4k | |
| Independent Director | 9.3yrs | US$377.75k | 0.062% $ 1.5m | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 9.4yrs | US$398.22k | 0.015% $ 376.1k | |
| Independent Director | 10.1yrs | US$387.75k | 0.021% $ 508.1k | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 9.3yrs | US$398.22k | 0.015% $ 361.4k | |
| Independent Chairman of the Board | 12.3yrs | US$386.13k | 0.062% $ 1.5m | |
| Independent Director | 4.6yrs | US$377.75k | 0.011% $ 258.0k |
9.4yrs
Average Tenure
66yo
Average Age
Experienced Board: 0A4W's board of directors are considered experienced (9.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/29 10:44 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ACADIA Pharmaceuticals Inc. is covered by 36 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Ishan Majumdar | Baptista Research |
| Esther Lannie Hong | Berenberg |